Olena Martyniuk

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Maryna Bondar

National Cancer Institute

ТB

Т. Borikun

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

Taras Zadvornyi

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

N Yu Lukianova

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

L. A. Syvak

National Cancer Institute

Oleksandr Mushii

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

ВФ

В Ф Чехун

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

Tetiana Tarasenko

National Cancer Institute

Elena Kashuba

Karolinska Institutet

Mykhailo Krotevych

National Cancer Institute

Cooperative Institutions

R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

National Academy of Sciences of Ukraine

National Cancer Institute

Ministry of Health

National Cancer Institute

Ivano-Frankivsk National Medical University

Kyiv City Clinical Oncology Center

Cancer Institute (WIA)

Institute of Neurology, Psychiatry and Narcology

Yonsei University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

EXPRESSION PROFILE OF miR-145, -182, -21, -27a, -29b, and -34a IN BREAST CANCER PATIENTS OF YOUNG AGE

Experimental Oncology (2024)

В Ф Чехун Т. Borikun Oleksandr Mushii Taras Zadvornyi Olena Martyniuk

Background. Breast cancer (BC) in young women remains a significant public health concern. While progress has been made in understanding the etiology, diagnosis, and treatment of BC in this population, challenges persist. The identification and utilization of prognostic biomarkers offer valuable tools for tailoring treatment strategies and improving outcomes for BC patients. Aim. To evaluate the relationship between the expression of tumor-associated microRNAs and the clinical and pathological features of BC in young patients. Materials and Methods. The work is based on the results of the examination and treatment of 50 women younger than 45 years with stage I—II BC. miR-145, -182, -21, -27a, -29b, and -34a expression in tumor samples was analyzed by the real-time reverse transcription polymerase chain reaction. Results. Higher expression of miR-182, -21, and -29b and lower levels of miR-27a were associated with tumor stage in young BC patients. Patients without lymph node metastases (N0) had significantly higher levels of miR-182, -27a, and -34a and lower levels of miR-29b compared to N1 cases (p < 0.05). Expression of miR-145, -182, -21, -27a, and -29b was associated with molecular BC subtypes. Conclusion. Obtained results show that a high malignancy degree of BC in young women is associated with an increase in the miR-182, -21, -29b, and -34a expressions and a decrease in the miR-27a level in the tumor tissue, which indicates the prospects of the use of them for predicting the aggressiveness of the disease.

Etiology

10.15407/exp-oncology.2023.04.421

Cite

Citations (2)

PO114 PREVALENCE AND CLINICAL FEATURES OF HER2-LOW BREAST CANCER AMONG UKRAINIAN POPULATION

The Breast (2023)

Maryna Bondar Tetiana Tarasenko Olena Martyniuk L. A. Syvak

Ukrainian

10.1016/s0960-9776(23)00678-1

Cite

Citations (0)

FEATURES OF COL1A1 EXPRESSION IN BREAST CANCER TISSUE OF YOUNG PATIENTS

Experimental Oncology (2023)

В Ф Чехун Oleksandr Mushii Taras Zadvornyi Т. Borikun Olena Martyniuk

Background. In the last decades, the incidence of breast cancer (BCa) in young women has been increasing steadily. The quantitative indicators of expression of collagen, which play important role in stromal microenvironment, and their association with the age and survival rates of BCa patients have not been yet definitively clarified. Aim. To investigate the relationship between the COL1A1 gene expression at the mRNA and protein levels in BCa tissue and the clinicopatological features and survival rates of BCa patients of different age groups. Materials and Methods. The study was conducted on the clinical material of 50 patients with stage I—III BCa. COL1A1 gene expression at the mRNA and protein levels in BCa tissue were studied using the real-time PCR and immunohistochemical methods, as well as the bioinformatic analysis (UALCAN and Kaplan — Meier Plotter databases). Results. The bioinformatic analysis showed that BCa tissue is characterized by 6.0 times (p < 0.05) higher level of COL1A1 mRNA compared to normal breast tissue. The correlation of COL1A1 expression at the mRNA and protein levels with the molecular subtype of neoplasms was demonstrated. According to Kaplan — Meier Plotter database, a low level of expression of COL1A1 protein level in BCa tissue is associated with lower rates of relapse-free survival of patients. The ex vivo study of the clinical material revealed a decrease in COL1A1 protein expression in tumor tissue of young patients with BCa of T3 category (p < 0.0374), low differentiation grade (p < 0.0163) and basal molecular subtype (p < 0.0001). A correlation between the expression of COL1A1 at the mRNA and protein levels and the expression status of estrogen receptors (p < 0.0001) and progesterone receptors (p < 0.0040) was established. The relapse-free 3-year survival rate of young BCa patients is significantly lower in the presence of a low COL1A1 optical density index in the tumor tissue. Conclusions. The identified relationship between COL1A1 expression and such indicators of BCa malignancy as tumor size, differentiation grade, molecular subtype, receptor status, and the recurrencefree survival of patients indicates the prospects of its use to predict the aggressiveness of the BCa course in young patients.

Human Protein Atlas

10.15407/exp-oncology.2023.03.351

Cite

Citations (2)

PO110 ASSESSMENT OF EARLY PROGRESSION RISK FOR PATIENT WITH ESR1 MUTATIONS AND HORMONE RECEPTOR POSITIVE (HR+)/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)

The Breast (2023)

Tetiana Tarasenko L. A. Syvak Olena Martyniuk Maryna Bondar

Trastuzumab, other innovative drugs became available, including lapatinib.Therefore, the Dushanbe City Counseling Center, together with the Republican Cancer Institute and the NGO Avesta, recruited the humanitarian drug lapatinib to treat women with metastatic cancer and HER-positive status.A total of 56 women with advanced and metastatic cancer were selected.The primary diagnosis of disseminated breast cancer was in 19 women (34%), and metastatic relapse was in 37 women(66%).CNS metastases were found in 11 women, and liver metastases were found in 26 women.Eleven women (19%) received anthracycline therapy before lapatinib administration.The women were separated by age: 31 women were in the 45-60-year group, and 25 women were in the 60-75 year group.All women received positive IHC and FISH tests to confirm HER-positive status.Results of lapatinib treatment and the drug's effect on metastatic cancer: Women were treated with lapatinib for 24 weeks at a dose of 1,250 mg orally once daily on Days 1-21 continuously in combination with capecitabine.After treatment evaluation, brain metastases had not progressed in 7(12%) women, and two women experienced a decrease in the size of their metastases.8(14%) women with liver metastases had no progression of liver metastases, and 23 women had progression and growth of metastases.Impact of humanitarian delivery of lapatinib on the cancer care system: 1.The Cancer Institute opened a lab to diagnose HER2 status. 2. The Oncology Institute started working on a protocol for the treatment of women with advanced and metastatic cancer, which is vital for a country with limited resources.PO109

HER2 negative

10.1016/s0960-9776(23)00674-4

Cite

Citations (0)